A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Veeva Systems (VEEV) has drawn fresh attention after ...

As noted previously, when Veeva ended its licence agreement with Salesforce, it not only triggered a battle royale for domination of big pharma CRM, it began the first massive use case for adoption of ...

A number of stocks fell in the afternoon session after markets pulled back as reports surfaced that Chinese customs authorities blocked Nvidia's H200 AI chips, effectively halting their entry despite ...

PLEASANTON, Calif., Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new environmental monitoring (EM) solution to advance quality control (QC) for manufacturing operations.

The latest announcement is out from Veeva Systems ( (VEEV)). On January 5, 2026, Veeva Systems announced that its board had authorized the company’s first-ever share repurchase program, allowing the ...

Veeva Systems is rated a buy, with strong revenue and EPS growth, raised FY2026 guidance, and a misunderstood sell-off creating a long-term opportunity. VEEV's migration to Vault CRM is progressing ...

The Details: Veeva reported quarterly earnings of $2.04 per share, which beat the analyst estimate of $1.95. Quarterly revenue of $811.2 million beat the Street estimate of $792.82 million.

The latest announcement is out from Veeva Systems ( (VEEV)). On November 17, 2025, Veeva Systems Inc. announced that Kristine Diamond, the Chief Accounting Officer, will resign from her position ...

Veeva Systems Inc. (NYSE:VEEV) is one of the best digital health stocks to buy now. On November 4, 2025, Veeva announced that its Veeva Basics solution has been adopted by “more than 100 biotechs” to ...

The yearslong legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries setting aside their differences to launch a series of clinical and commercial ...